Moderna, Inc. (MRNA) experienced a significant price surge during Monday's intraday trading session, with shares soaring 5.05%.
The sharp increase follows positive analyst action, as Piper Sandler raised its price target on Moderna to $69 from $63 while maintaining an Overweight rating on the stock. This upward revision reflects growing analyst confidence in the company's prospects and typically signals to investors that the stock may be undervalued relative to its potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.